UPDATE: Advanced BioHealing launches Dermagraft trial
November 18, 2009 by MassDevice staff
The Westport, Conn.-based tissue regeneration company will study the effectiveness of its bio-engineering skin substitute in helping venous leg ulcers to heal, in the largest-ever randomized, controlled clinical study of bioengineered skin replacement
From snip, snip to step, step in only a few months.
Advanced BioHealing Inc. launched a Phase III clinical trial of its Dermagraft bio-engineered skin substitute in patients with venous leg ulcers.
The Westport, Conn.-based tissue regeneration company said the Dermagraft is designed to help restore damaged tissue and support the body's natural healing process. The Food & Drug Administration already cleared the product to treat diabetic foot ulcers; ABH said more than 1,000 wound care and outpatient clinics in the U.S. use it.
Similar entries
- Show full page
- Login to post comments
-
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
NEWS
Medical device tax: Ohio's industry pushes repeal while GOP group gets hyper-political
Ohio-based medical device makers meet with local legislators to discuss efforts to repeal the...
MassDevice.com +3 | The top 3 med-tech stories for May 15, 2012.
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on...
Electromed CEO Robert Hansen retires after 20 years at the helm | Personnel Moves
Electromed founder, chairman & CEO Robert Hansen announces his retirement after 20 years leading...
St. Jude Medical gains on Goldman upgrade | Wall Street Beat
St. Jude Medical's shares get a 2% lift from an upgrade by a Goldman Sachs analyst.
SEC closed probe of Zoll's Middle East sales just ahead of $2.3B Asahi merger
Just weeks before a $2.3 billion acquisition by Asahi Kasei closed, the Securities & Exchange...
